Fig. 1: VSV vector design and characterization.
a Schematic representation depicting the genomic organization of the VSV vectors. N nucleoprotein, P phosphoprotein, M matrix protein, G glycoprotein, L polymerase, EBOV-GP Ebola virus full-length glycoprotein, EBOV GP∆GC∆MLD Ebola virus glycoprotein lacking the glycan cap and mucin-like domain, CCHFV-NP CCHFV full-length nucleocapsid protein, CCHFV-GPC_del53 CCHFV glycoprotein precursor lacking 53 amino acid sequences of the carboxy terminal (see also Supplementary Fig. 1A). b Intracellular protein expression. Vero E6 cells were infected with each virus at an MOI of 0.01. CCHFV-NP, Gc, and EBOV-GP expression was detected by immunofluorescence following permeabilization. VSV-M served as a control (magnification, 10x). c In vitro growth kinetics of the VSV vectors. Vero E6 cells were infected with VSV vectors at an MOI of 0.01. Cell culture supernatants were collected at the indicated time points. The infectious virus was titrated using a TCID50 assay. One representative experiment in triplicate is shown. Statistical significance was analyzed using one-way ANOVA with Tukey’s multiple comparisons test in Prism 10 (GraphPad), and results are indicated as *p < 0.05, **p < 0.01, and ***p < 0.001. Comparisons with p values >0.05 were not displayed. Data shown as geometric mean plus standard deviation. Graphical illustrations were prepared with Adobe Illustrator version 28.7 (public domain).
